DRIO vs. APYX, NSPR, XAIR, DXR, CTSO, LUCD, AMIX, GBS, ICCM, and CTCX
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include Apyx Medical (APYX), InspireMD (NSPR), Beyond Air (XAIR), Daxor (DXR), Cytosorbents (CTSO), Lucid Diagnostics (LUCD), Autonomix Medical (AMIX), GBS (GBS), IceCure Medical (ICCM), and Carmell (CTCX). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
Apyx Medical has a net margin of -45.20% compared to DarioHealth's net margin of -165.96%. DarioHealth's return on equity of -48.84% beat Apyx Medical's return on equity.
DarioHealth has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
In the previous week, Apyx Medical had 7 more articles in the media than DarioHealth. MarketBeat recorded 13 mentions for Apyx Medical and 6 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.62 beat Apyx Medical's score of 0.08 indicating that DarioHealth is being referred to more favorably in the media.
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 55.3% of Apyx Medical shares are owned by institutional investors. 15.7% of DarioHealth shares are owned by insiders. Comparatively, 13.1% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
DarioHealth received 161 more outperform votes than Apyx Medical when rated by MarketBeat users. Likewise, 67.04% of users gave DarioHealth an outperform vote while only 61.60% of users gave Apyx Medical an outperform vote.
Apyx Medical has higher revenue and earnings than DarioHealth. Apyx Medical is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
DarioHealth presently has a consensus price target of $4.05, indicating a potential upside of 118.92%. Apyx Medical has a consensus price target of $6.17, indicating a potential upside of 337.35%. Given Apyx Medical's higher probable upside, analysts clearly believe Apyx Medical is more favorable than DarioHealth.
Summary
DarioHealth beats Apyx Medical on 9 of the 16 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
